Clinical Trials List
2016-09-01 - 2020-05-31
Phase III
Terminated3
ICD-10C64
Malignant neoplasm of kidney, except renal pelvis
ICD-9189.0
Malignant neoplasm of kidney, except pelvis
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 沈書慧 Division of Radiology
- Yen-Hwa Chang Division of Urology
- 潘競成 Division of Others
- Yi-Hsiu Huang Division of Urology
- Tzu-Ping Lin Division of Urology
- Tzu-chun Wei Division of Urology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chi-Ping Huang Division of Urology
- Chi-Rei Yang Division of Urology
- Hsi-Chin Wu Division of Urology
- Ching-Chan Lin Division of Hematology & Oncology
- 陳冠亨 Division of Urology
- Po-Fan Hsieh Division of Urology
- Su-Peng Yeh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
Audit
None
Taiwan National PI
Co-Principal Investigator
- Mengting Peng Division of Hematology & Oncology
- See-Tong Pang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
4 Terminated
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
19 participants
-
Global
840 participants
